12,256 Shares in Moderna, Inc. $MRNA Bought by IFG Advisory LLC

IFG Advisory LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,256 shares of the company’s stock, valued at approximately $361,000.

Other institutional investors have also added to or reduced their stakes in the company. Douglas Lane & Associates LLC increased its holdings in Moderna by 14.4% during the fourth quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company’s stock worth $38,085,000 after buying an additional 163,031 shares during the last quarter. Banco Santander S.A. increased its holdings in Moderna by 22.1% during the third quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock worth $5,577,000 after buying an additional 39,056 shares during the last quarter. Sigma Planning Corp acquired a new position in Moderna during the fourth quarter worth $907,000. Gateway Investment Advisers LLC increased its holdings in Moderna by 1,445.1% during the fourth quarter. Gateway Investment Advisers LLC now owns 140,454 shares of the company’s stock worth $4,142,000 after buying an additional 131,364 shares during the last quarter. Finally, Telemark Asset Management LLC acquired a new position in Moderna during the third quarter worth $12,915,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on MRNA shares. Citigroup restated a “neutral” rating on shares of Moderna in a report on Monday, February 16th. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research report on Friday, May 1st. Jefferies Financial Group set a $37.00 price objective on shares of Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Finally, Evercore set a $35.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $35.73.

Insider Activity

In other news, Director Abbas Hussain sold 5,682 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the sale, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. The trade was a 32.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $183,800.16. The trade was a 70.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 68,281 shares of company stock valued at $3,280,293. 10.80% of the stock is owned by company insiders.

Moderna Stock Performance

MRNA stock opened at $47.19 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The company has a fifty day moving average price of $50.24 and a two-hundred day moving average price of $42.52. Moderna, Inc. has a one year low of $22.28 and a one year high of $59.55. The stock has a market cap of $18.72 billion, a price-to-earnings ratio of -5.79 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same period last year, the firm earned ($2.52) earnings per share. The company’s revenue for the quarter was up 260.2% compared to the same quarter last year. Equities analysts anticipate that Moderna, Inc. will post -6.49 EPS for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.